The Muscle Problem Gets a Mechanistic Answer
Issue #5 · June 14, 2026
This Week: The GLP-1 Muscle Problem Gets a Real Mechanistic Answer
There is a number that keeps coming up in GLP-1 research, and it should make anyone on semaglutide or tirzepatide sit up: up to 45% of the weight lost on these drugs can come from skeletal muscle, not fat. That statistic has been bouncing around the literature since 2024, confirmed by multiple human trials and a Lancet meta-analysis. For a 50-year-old woman losing 40 pounds on Ozempic, that could mean shedding 18 pounds of lean tissue — the kind that keeps bones dense, metabolisms running, and frailty at bay.
The standard advice — eat more protein, lift heavy things — is correct but incomplete. Many patients on GLP-1 drugs are starting from a deconditioned baseline, and even aggressive protein targets (1.2–1.6 g/kg/day) do not fully close the gap. Peptide stacks like BPC-157 and TB-500 support tissue repair, but they do not directly address the metabolic-driven muscle catabolism that GLP-1 receptor agonists appear to trigger at the cellular level.
This week, a team at the University of Alberta published a study in JCI Insight that changes the conversation. They found that ketone ester co-administration with semaglutide preserved skeletal muscle mass and function in obese mice — without blunting fat loss. The combo group got just as lean as the semaglutide-only group, but they kept their muscle. That is a significant finding, and it arrives at a moment when the GLP-1 ecosystem desperately needs solutions to its biggest structural weakness.
One article this week, but it is a dense one with real mechanistic depth. We are going to spend some time unpacking what the University of Alberta team actually found, why the mitochondrial angle matters, and what this means for anyone currently running a GLP-1 protocol. Let’s get into it.
Ketone Esters Could Save Your Muscles on Semaglutide — New Study Shows
The study, led by Dr. Jason Dyck at the University of Alberta’s Cardiovascular Research Centre, used an elegant three-arm design: obese glucose-intolerant mice received either vehicle (control), semaglutide alone, or semaglutide plus a beta-hydroxybutyrate (BHB) generating ketone ester. After three weeks, the semaglutide-only group showed the expected problems — reduced lean mass, impaired muscle strength, suppressed mitochondrial gene expression, and elevated atrophy-related genes. The molecular machinery that breaks down muscle fiber was running hot. The ketone ester group? None of that happened. Skeletal muscle mass and function were preserved. Fat loss was uncompromised.
The mechanism is the real story here. Semaglutide does not just reduce your appetite and let your muscles fend for themselves. It actively disrupts mitochondrial function in muscle cells — the powerhouses that generate ATP and keep muscle fibers healthy. It also upregulates atrophy-related genes, which are essentially the body’s instructions for dismantling muscle tissue. These are direct biochemical effects on skeletal muscle, separate from the indirect consequences of eating less protein.
BHB counteracts both of those downstream pathways. This is important because BHB is not just an alternative fuel source that your liver cranks out during fasting. It is a signaling molecule with documented biological activity across multiple systems. A 2026 review in Nutrients by researchers at Italy’s National Institute of Health and Science on Aging laid out the mechanisms in detail: BHB acts as a histone deacetylase (HDAC) inhibitor, which means it influences gene expression patterns involved in muscle maintenance and stress resistance. It modulates the NF-kB inflammatory pathway — a key driver of muscle wasting. And it directly supports mitochondrial biogenesis, the exact process that semaglutide appears to shut down in muscle tissue.
What makes this particularly interesting for the GLP-1 community is that ketone esters are already available, already used in performance contexts, and have a reasonable safety profile. Elite athletes, military programs, and Olympic endurance teams have all tested BHB supplementation. Side effects are generally limited to GI discomfort at high doses. Typical research doses range from 25–50 grams per day of BHB monoester, and circulating BHB levels reach 0.5–3.0 mM within 30 minutes of ingestion — well within the physiological range that appears to drive the protective effects seen in this study.
Now, the caveats. This is a preclinical mouse study with a three-week treatment window, not a human clinical trial running 12–18 months. The dose translation to humans is not established. The mice were obese and glucose-intolerant but otherwise young and otherwise healthy — a different population than the typical GLP-1 patient who may have comorbidities. The University of Alberta team was explicit about this: their findings support ketone therapy as a promising strategy that warrants clinical evaluation, but they are not prescribing a protocol.
We graded this one a B — Promising Preclinical, Human Trials Needed. The journal is high-impact (JCI Insight), the experimental design is clean, the mechanistic story is coherent, and the mitochondrial gene expression data adds molecular-level evidence that goes beyond simple observation. But it is still a 3-week mouse study. Until human trials land, the best approach is layered: prioritize protein (1.2–1.6 g/kg/day), resistance train (non-negotiable on GLP-1 therapy), monitor body composition with DEXA or BIA (do not rely on the scale alone), and consider ketone esters as a potential third layer of protection for your muscles.
What to Watch Next Week
The GLP-1 landscape is not slowing down. Retatrutide’s phase 3 TRANSCEND-T2D-1 data just landed in The Lancet showing superior glycemic control, and the muscle preservation question is going to be central to how these next-generation drugs get adopted and prescribed. If ketone esters prove out in human trials, they could become a standard companion therapy for anyone on GLP-1 receptor agonists — not as a replacement for the fundamentals (protein, resistance training, body composition monitoring), but as a pharmacological backstop that addresses the mitochondrial disruption these drugs cause.
We are also tracking emerging research on MOTS-c and other mitochondrial peptides that may offer complementary muscle-protective effects through different mechanisms. A recent Frontiers in Medicine study showed partial protection against skeletal muscle deterioration with MOTS-c, and the intersection of mitochondrial peptides and GLP-1 therapy is shaping up to be one of the most active research frontiers in longevity medicine. The next 12 months will be telling — if human ketone ester trials replicate what we saw in mice this week, the standard of care for GLP-1 patients could look very different by mid-2027. Expect more on that in the coming weeks. Stay tuned.
Model Your Stack
This week’s deep dive covered ketone esters, BPC-157, and TB-500 — three compounds that attack the muscle preservation problem from completely different angles. Ketone esters protect mitochondrial function and suppress atrophy gene expression. BPC-157 supports tissue repair and gut integrity, which matters when you are eating less on GLP-1 drugs and your GI tract is under stress. TB-500 promotes muscle recovery and reduces inflammation through actin regulation. The BioStack Generator lets you model how these compounds interact against your specific goals, current medications, and dosing schedule. See where the synergies actually are (not where supplement marketing says they are), flag potential interactions, and build a protocol grounded in the research. Takes 2 minutes.
Turn This Week's Research Into Your Protocol
The BioStack Generator models how this week's compounds interact — receptor overlap, dosing timing, contraindications — and builds a personalised protocol from the evidence.
Build Your BioStackFree · No account required